CPHI CHINA PHARMA HOLDINGS, INC.
Pharmaceutical Preparations · NYSE · SEC CIK 1106644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.4%
TTM net income YoY-79.5%
TTM EPS YoY71.8%
Revenue 3-yr CAGR-17.9%
Net income 3-yr CAGR—
Margins
Gross margin14.2%
Operating margin-130.5%
Net margin-132.8%
FCF margin—
EBITDA margin-89.0%
Returns
ROE-24.2%
ROA-18.3%
ROIC (approx.)-20.5%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets16.8%
Debt / equity0.00x
Current ratio0.77x
Interest coverage-157.66x
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.15M | $948,340 | $983,536 | $1.23M | $756,217 | $1.03M | $1.14M | $1.13M |
| Cost of revenue | $1.06M | $864,774 | $698,049 | $1.08M | $815,871 | $1.11M | $1.27M | $1.29M |
| Gross profit | $91,974 | $83,566 | $285,487 | $150,775 | -$59,654 | -$87,010 | -$136,061 | -$160,589 |
| R&D expense | $16,369 | $19,135 | $83,762 | $190,041 | $40,321 | $20,952 | $29,587 | $547 |
| SG&A expense | $1.31M | $1.38M | $1.23M | $1.08M | $424,827 | $440,834 | $507,182 | $859,373 |
| Operating income | -$1.88M | -$1.43M | -$1.12M | -$1.20M | -$628,145 | -$652,120 | -$758,618 | -$1.20M |
| Interest expense | $10,414 | $9,306 | $9,085 | $6,879 | $6,798 | $6,771 | $6,787 | $6,802 |
| Pretax income | -$1.90M | -$1.46M | -$1.14M | -$1.22M | -$651,482 | -$528,367 | -$785,572 | -$1.22M |
| Net income | -$1.90M | -$1.46M | -$1.14M | -$1.22M | -$651,482 | -$528,367 | -$785,572 | -$1.22M |
| EBITDA | -$1.71M | -$1.28M | -$136,694 | -$702,770 | -$470,069 | -$488,617 | -$429,305 | -$747,963 |
| EPS (basic) | -0.04 | -0.04 | -0.04 | — | -0.17 | -0.16 | -0.24 | — |
| EPS (diluted) | -0.04 | -0.04 | -0.04 | — | -0.17 | -0.16 | -0.24 | — |
| Weighted avg. shares (diluted) | 42.42M | 40.52M | 25.60M | — | 3.87M | 3.23M | 3.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.68M | $304,874 | $168,474 | $345,112 | $267,625 | $625,032 | $412,688 | $626,879 |
| Receivables | $196,588 | $181,621 | $196,262 | $241,412 | $224,638 | $268,793 | $328,901 | $232,140 |
| Inventory | $1.32M | $1.36M | $1.50M | $1.62M | $1.65M | $1.68M | $1.98M | $2.27M |
| Current assets | $5.39M | $2.01M | $2.00M | $2.35M | $2.33M | $2.70M | $2.85M | $3.27M |
| PP&E, net | $4.12M | $4.22M | $4.30M | $4.39M | $4.50M | $4.63M | $4.78M | $4.88M |
| Intangibles | $37.30M | $38.34M | $38.67M | $24.08M | $8.78M | $6.44M | $6.57M | $6.70M |
| Total assets | $46.93M | $44.71M | $45.14M | $31.00M | $15.80M | $13.77M | $14.22M | $14.89M |
| Current liabilities | $7.03M | $7.68M | $7.27M | $7.40M | $6.62M | $5.25M | $5.12M | $5.02M |
| Short-term debt | $1.57M | $1.64M | $1.47M | $1.44M | $1.41M | $1.41M | $1.15M | $1.14M |
| Total liabilities | $7.86M | $8.53M | $8.12M | $8.26M | $7.49M | $7.30M | $7.25M | $7.14M |
| Shareholders' equity | $39.07M | $36.18M | $37.02M | $22.74M | $8.31M | $6.46M | $6.97M | $7.75M |
| Shares outstanding | 43.02M | 40.52M | 40.52M | 5.52M | 3.26M | 3.26M | 3.26M | 3.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.11M | -$32,828 | -$55,292 | $151,990 | -$236,987 | $274,307 | -$73,676 | $238,474 |
| Capital expenditure | — | — | — | $454 | $611 | -$65 | $58,324 | $19,545 |
| Free cash flow | — | — | — | $151,536 | -$237,598 | $274,372 | -$132,000 | $218,929 |
| Investing cash flow | — | — | — | -$5,767 | -$40,598 | $65 | -$58,324 | -$272,852 |
| Financing cash flow | $4.50M | $120,118 | -$79,325 | -$72,592 | -$122,214 | -$29,188 | -$76,820 | $6,802 |
| Depreciation & amortization | $163,063 | $150,327 | $980,570 | $497,425 | $158,076 | $163,503 | $329,313 | $448,073 |
| Stock-based compensation | — | $0 | $0 | — | — | $0 | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.